These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 22387453)

  • 41. Characterization of the cellular and humoral immune response to outer surface protein C and outer surface protein 17 in children with early disseminated Lyme borreliosis.
    Pohl-Koppe A; Kaunicnik A; Wilske B
    Med Microbiol Immunol; 2001 Sep; 189(4):193-200. PubMed ID: 11599789
    [TBL] [Abstract][Full Text] [Related]  

  • 42. OspC phylogenetic analyses support the feasibility of a broadly protective polyvalent chimeric Lyme disease vaccine.
    Earnhart CG; Marconi RT
    Clin Vaccine Immunol; 2007 May; 14(5):628-34. PubMed ID: 17360854
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Construction and analysis of variants of a polyvalent Lyme disease vaccine: approaches for improving the immune response to chimeric vaccinogens.
    Earnhart CG; Marconi RT
    Vaccine; 2007 Apr; 25(17):3419-27. PubMed ID: 17239505
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Epitope mapping of Borrelia burgdorferi OspC protein in homodimeric fold.
    Norek A; Janda L
    Protein Sci; 2017 Apr; 26(4):796-806. PubMed ID: 28142214
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oral immunization with recombinant lactobacillus plantarum induces a protective immune response in mice with Lyme disease.
    del Rio B; Dattwyler RJ; Aroso M; Neves V; Meirelles L; Seegers JF; Gomes-Solecki M
    Clin Vaccine Immunol; 2008 Sep; 15(9):1429-35. PubMed ID: 18632920
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characterization of the P13 membrane protein of Borrelia burgdorferi by mass spectrometry.
    Nilsson CL; Cooper HJ; Håkansson K; Marshall AG; Ostberg Y; Lavrinovicha M; Bergström S
    J Am Soc Mass Spectrom; 2002 Apr; 13(4):295-9. PubMed ID: 11951966
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Isolation and purification of recombinant outer surface protein C (rOspC) of Borrelia burgdorferi sensu lato.
    Krupka M; Bĕláková J; Sebestová M; Tuhácková J; Raska M; Vrzal V; Weigl E
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):261-4. PubMed ID: 16601766
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Omics and bioinformatics applied to vaccine development against Borrelia.
    Bencurova E; Gupta SK; Oskoueian E; Bhide M; Dandekar T
    Mol Omics; 2018 Oct; 14(5):330-340. PubMed ID: 30113617
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Humoral immunity reflects altered T helper cell bias in Borrelia burgdorferi-infected gamma delta T-cell-deficient mice.
    Bockenstedt LK; Shanafelt MC; Belperron A; Mao J; Barthold SW
    Infect Immun; 2003 May; 71(5):2938-40. PubMed ID: 12704174
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characterization of multiprotein complexes of the Borrelia burgdorferi outer membrane vesicles.
    Yang X; Promnares K; Qin J; He M; Shroder DY; Kariu T; Wang Y; Pal U
    J Proteome Res; 2011 Oct; 10(10):4556-66. PubMed ID: 21875077
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Structural analysis of glycolipids from Borrelia burgdorferi.
    Hossain H; Wellensiek HJ; Geyer R; Lochnit G
    Biochimie; 2001 Jul; 83(7):683-92. PubMed ID: 11522398
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adjuvancy enhancement of muramyl dipeptide by modulating its release from a physicochemically modified matrix of ovalbumin microspheres. I. In vitro characterization.
    Puri N; Kou JH; Sinko PJ
    J Control Release; 2000 Oct; 69(1):53-67. PubMed ID: 11018546
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunopotentiating conjugates.
    Stewart-Tull DE
    Vaccine; 1985 Mar; 3(1):40-4. PubMed ID: 3890399
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Past, present, and future of Lyme disease vaccines: antigen engineering approaches and mechanistic insights.
    Chen WH; Strych U; Bottazzi ME; Lin YP
    Expert Rev Vaccines; 2022 Oct; 21(10):1405-1417. PubMed ID: 35836340
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Experimental and Computational Observations of Immunogenic Cobalt Porphyrin Lipid Bilayers: Nanodomain-Enhanced Antigen Association.
    Federizon J; Feugmo CGT; Huang WC; He X; Miura K; Razi A; Ortega J; Karttunen M; Lovell JF
    Pharmaceutics; 2021 Jan; 13(1):. PubMed ID: 33466686
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting Human Thrombus by Liposomes Modified with Anti-Fibrin Protein Binders.
    Petroková H; Mašek J; Kuchař M; Vítečková Wünschová A; Štikarová J; Bartheldyová E; Kulich P; Hubatka F; Kotouček J; Knotigová PT; Vohlídalová E; Héžová R; Mašková E; Macaulay S; Dyr JE; Raška M; Mikulík R; Malý P; Turánek J
    Pharmaceutics; 2019 Dec; 11(12):. PubMed ID: 31810280
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunogenicity of the Lyme disease antigen OspA, particleized by cobalt porphyrin-phospholipid liposomes.
    Federizon J; Frye A; Huang WC; Hart TM; He X; Beltran C; Marcinkiewicz AL; Mainprize IL; Wills MKB; Lin YP; Lovell JF
    Vaccine; 2020 Jan; 38(4):942-950. PubMed ID: 31727504
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Position of His-Tag in Recombinant OspC and Application of Various Adjuvants Affects the Intensity and Quality of Specific Antibody Response after Immunization of Experimental Mice.
    Krupka M; Masek J; Barkocziova L; Turanek Knotigova P; Kulich P; Plockova J; Lukac R; Bartheldyova E; Koudelka S; Chaloupkova R; Sebela M; Zyka D; Droz L; Effenberg R; Ledvina M; Miller AD; Turanek J; Raska M
    PLoS One; 2016; 11(2):e0148497. PubMed ID: 26848589
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants.
    Hanson MC; Crespo MP; Abraham W; Moynihan KD; Szeto GL; Chen SH; Melo MB; Mueller S; Irvine DJ
    J Clin Invest; 2015 Jun; 125(6):2532-46. PubMed ID: 25938786
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular adjuvants based on nonpyrogenic lipophilic derivatives of norAbuMDP/GMDP formulated in nanoliposomes: stimulation of innate and adaptive immunity.
    Knotigová PT; Zyka D; Mašek J; Kovalová A; Křupka M; Bartheldyová E; Kulich P; Koudelka Š; Lukáč R; Kauerová Z; Vacek A; Horynová MS; Kozubík A; Miller AD; Fekete L; Kratochvílová I; Ježek J; Ledvina M; Raška M; Turánek J
    Pharm Res; 2015 Apr; 32(4):1186-99. PubMed ID: 25630814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.